r-162

R162 is an effective glutamate dehydrogenase 1 (GDH1) inhibitor.

Balapiravir (R1626, Ro 4588161) is the prodrug of a nucleoside analogue inhibitor of the hepatitis C virus (HCV) RNA-dependent RNA polymerase (R1479, RG1479). IC50 Value: Target: HCV Balapiravir was discontinued for safety reasons in 28-36% of patients (m

Balapiravir HCl, an NS5B inhibitor, is used potentially for the treatment of HCV infection.

TH-162, also known as (R)-PIA and Adenosine, N-(1-methyl-2-phenylethyl)-, (R)-, is an agonist of the A1 adenosine receptor. Affinity for adenosine receptors is approx. 100× that of the (+)-isomer.

Palmitic acid-1,2,3,4-13C4 is intended for use as an internal standard for the quantification of palmitic acid by GC- or LC-MS. Palmitic acid (T2908) is a common 16-carbon saturated fat that represents 10-20% of human dietary fat intake and comprises approximately 25 and 65% of human total plasma lipids and saturated fatty acids, respectively.1,2Acylation of palmitic acid to proteins facilitates anchoring of membrane-bound proteins to the lipid bilayer and trafficking of intracellular proteins, promotes protein-vesicle interactions, and regulates various G protein-coupled receptor functions.1Red blood cell palmitic acid levels are increased in patients with metabolic syndrome compared to patients without metabolic syndrome and are also increased in the plasma of patients with type 2 diabetes compared to individuals without diabetes.3,4